AMAG Pharmaceuticals to Acquire Cord Blood Registry AMAG Pharmaceuticals, Inc. announced that it has entered into a definitive agreement to acquire Cord Blood Registry®, the world’s largest stem cell collection and storage company serving pregnant women and their families, for $700 million. [Cord Blood Registry®] Press Release Amarna Therapeutics Teaming Up with Austrian CBmed in the Development of Immunotherapies Amarna Therapeutics announced that it has entered into a cooperation with Austrian Center for Biomarker Research in Medicine (CBmed), for the development of immunotherapies against acute lymphoblastic leukemia, obesity, diabetes mellitus type 2 and atherosclerotic cardiovascular disease. [Amarna Therapeutics] Press Release Biogen and AGTC Enter Collaboration to Develop Gene Therapies in Ophthalmology Biogen and AGTC announced a broad collaboration and license agreement to develop gene-based therapies for multiple ophthalmic diseases. The collaboration will focus on the development of a portfolio of AGTC’s therapeutic programs, including both a clinical stage candidate and a pre-clinical candidate for orphan diseases of the retina that can lead to blindness in children and adults. [Biogen] Press Release STEMCELL Technologies Launches Innovative Products to Support CAR T Cell Research STEMCELL Technologies Inc. announced the launch of ImmunoCult™ Human T Cell Activator reagents and ImmunoCult™-XF T Cell Expansion Medium to support T cell researchers in their goal to develop CAR T cell immunotherapeutics. The products provide significant benefits compared to existing technologies. [STEMCELL Technologies Inc.] Press Release CTCA at Western Launches 3rd New Clinical Trial Combining Immunotherapy with Chemotherapy Cancer Treatment Centers of America® (CTCA) at Western Regional Medical Center, has begun a new Phase Ib/II clinical trial using a new immunotherapy treatment for patients with advanced kidney, non-small cell lung cancer, pancreatic cancer and colorectal carcinoma. [Cancer Treatment Centers of America® (EurekAlert!)] Press Release TxCell Announces FDA Acceptance of IND for Ovasave TxCell SA announced that the United States Food and Drug Administration (FDA) has accepted TxCell’s Investigational New Drug (IND) application for the company’s lead product, Ovasave®, currently in a Phase IIb clinical trial for the treatment of patients with refractory Crohn’s disease. [TxCell SA] Press Release Exelixis Provides Update on Genentech’s Pending New Drug Application for Cobimetinib, an Exelixis-Discovered Compound Exelixis’ partner Genentech informed Exelixis that, in order to accommodate its review of a supplemental data submission, the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act action date for its review of Genentech’s New Drug Application for cobimetinib by the standard extension period of three months. [Exelixis, Inc.] Press Release R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labor and Welfare R-Japan Co., Ltd. obtained the license of cell processing facility under the Act on the Safety of Regenerative Medicine from the Ministry of Health, Labor and Welfare Kinki Bureau of Health and Welfare. [R-Japan Co., Ltd. (PR Newswire Association LLC)] Press Release |